An observational study in Pulmonary Hypertension, sponsored by University of Giessen. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2024-12-11.
Sponsored by University of Giessen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Hypertension, Pulmonary by University of Giessen — 5 open to participants now, 5 under way, none of them phase 3. Hypertension, Pulmonary · University of Giessen.
Among the 13 studies in Hypertension, Pulmonary by University of Giessen, this one is the 2nd largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 1993, is one of 11 observational ones, and was the 7th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.
Browse Hypertension, Pulmonary studies →5 of the 13 studies in Hypertension, Pulmonary by University of Giessen are open now, in 1 country. Recruiting first, the newest first:
University of Giessen · Sites in Germany
Ages 18+ · Healthy volunteers
University of Giessen · Sites in Germany
Ages 18+
University of Giessen · Sites in Germany
Healthy volunteers
University of Giessen · Sites in Germany
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 1 started in 1993.
This study's planned enrollment of 10,000 is above the median of 110 across 380 observational studies indexed under Hypertension, Pulmonary.
Median enrollment 57 across the 2 interventional studies, 500 across the 11 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Giessen is the lead sponsor of 95 studies on the registry; 22 are open to participants now.
1 of the studies in Hypertension, Pulmonary by University of Giessen that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06409624University of GiessenAssociation Between Biomarkers and Kidney Function Decline in Pulmonary Hypertension | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Hypertension, Pulmonary by University of Giessen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Giessen Pulmonary Hypertension Registry and Biobank
Long-term transplant-free survival and its determinants will be investigated in patients with Pulmonary Hypertension (diagnosed by right heart catheterization) within a prospective registry at a single referral center in Giessen, Germany.
Study population includes patients referred to our tertial PH expert center in Giessen with suspected PH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group 1 PH
Group 2 PH
Group 3 PH
Group 4 PH
Group 5 PH
Patient with invasively excluded PH
Survival
Transplant-free survival of PH patients
Time frame: Up to 20 years after enrollment
Started Jul 1993 (actual). Primary completion is estimated for Jul 2035, 504 months after the start.
Of 142 non-industry observational studies under Hypertension, Pulmonary, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 167. This study's planned 504 months is above that.
Counting every sponsor, half of 167 studies reached it within 59 months; a quarter within 24 and three quarters within 107.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Giessen